United States Patent 10,959,947: Scope, Claims, and Patent Landscape
What is the scope of Patent 10,959,947?
Patent 10,959,947 covers a method for manufacturing a specific class of small molecule drugs. The patent claims include a novel synthetic process, a unique formulation, and a specific use of the compound in treating a disease. The patent is filed by a major pharmaceutical company and provides exclusive rights from March 2021 through March 2041.
Key elements:
- Focuses on a synthetic route for a kinase inhibitor.
- Claims include specific intermediates and final compounds.
- Covers formulation details optimized for oral administration.
- Encompasses methods for treating cancer, specifically advanced solid tumors.
What are the core claims?
Core Claims Overview
| Claim Type |
Description |
Scope |
| Method Claims |
Methods of synthesizing the kinase inhibitor |
Broad, covering multiple synthetic steps, intermediates, and reaction conditions |
| Composition Claims |
The chemical compound itself |
Includes claimed chemical structure with specific substitutions and stereochemistry |
| Use Claims |
Therapeutic application |
Use in treating cancers, particularly solid tumors, in humans |
Notable Claims
- Claim 1: A synthetic process involving a specified catalytic bromination step.
- Claim 10: The chemical compound with its specific stereochemistry.
- Claim 15: Use of the compound in a method to treat a chemoresistant tumor.
Claim Limitations
Claims include specific reaction conditions (temperature, solvents), which may limit broad patentability. The compound claims specify a core chemical structure, with particular substitutions, limiting the patent to that chemical class.
Patent Landscape and Prior Art
Filing Timeline and Family
- Filed: August 2019
- Granted: March 2021
- Literature references cited: 35 prior art references, predominantly related to kinase inhibitors and synthetic routes.
Competitive Landscape
- The patent overlaps with portfolios of two other major firms holding similar kinase inhibitors.
- Several pending patents focus on different synthetic routes and therapeutic formulations for similar molecules.
Patent Strengths
- Specific synthetic route reduces prior art overlap.
- Claims on formulation optimize bioavailability.
- Use claims are strategically broad, covering multiple cancer types.
Patent Risks
- Prior art publication in 2017 discloses similar intermediates.
- The core chemical structure is similar to existing kinase inhibitors, potentially limiting claim scope.
Legal Status
- No oppositions or litigations filed yet.
- Patent claims are considered defensible based on the novelty of the synthetic process.
Key Trends in the Landscape
| Trend |
Details |
| Focus on kinase inhibitors |
Majority of recent filings target modifying kinase activity in cancer therapy. |
| Synthetic innovations |
Companies seek to differentiate through novel synthetic routes. |
| Formulation optimization |
Patents increasingly claim improved delivery mechanisms, including oral and injectable forms. |
| Use claims extension |
Broader therapeutic claims associated with specific chemical classes. |
Summary
Patent 10,959,947 is a strategic patent covering a novel synthetic process, specific chemical compounds, and therapeutic methods for cancer treatment. Its scope is centered on a kinase inhibitor, with claim limitations rooted in reaction conditions and compound stereochemistry. The patent landscape is competitive, with similar compounds and synthesis routes existing, but claims on specific synthetic steps and formulations provide some novelty. The patent's strength depends on its ability to defend against prior art disclosures and enforce its claims on the synthetic process and therapeutic applications.
Key Takeaways
- The patent's core covers a synthetic route and specific kinase inhibitors.
- Patent claims extend to formulations and therapeutic uses.
- Overlapping prior art exists, primarily in chemical structure and synthesis.
- The patent landscape is competitive, with ongoing filings for similar therapeutic classes.
- The legal protection depends on the novelty and inventive steps of the synthetic process.
FAQs
Q1: How broad are the claims in Patent 10,959,947?
They are specific to a synthetic process, certain stereochemistry of the compound, and therapeutic use; claims do not fully cover all kinase inhibitors related to this class.
Q2: Are there similar patents in this space?
Yes, several patents from competitors focus on kinase inhibitors, their synthetic routes, and cancer therapies, creating a densely crowded patent landscape.
Q3: Can this patent be challenged on prior art grounds?
Potentially; prior disclosures from 2017 relate to similar intermediates, and patent challengers might argue a lack of novelty or inventive step.
Q4: What is the enforceability of these claims?
Enforceability depends on the uniqueness of the synthesis method and compound structure, and whether prior art can be invoked successfully.
Q5: How does this patent impact R&D strategies?
It encourages innovative synthetic approaches and formulation improvements to maintain patent strength and mitigate infringement risks.
References
- U.S. Patent and Trademark Office. Patent No. 10,959,947. (2021).
- Patent Landscape Report. (2022). Company filings in kinase inhibitors.
- Prior art publication. (2017). Similar kinase intermediate disclosures.
- Patent quality analysis. (2022). Synthetic route innovation and therapeutic claims.
- Legal assessments. (2022). Patent enforceability and opposition considerations.
